Barbara McLaughlan discusses England's Cancer Drugs Fund (CDF) and suggests ways of securing a new, sustainable assessment and funding model for cancer medicines.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
